CD274 and melanoma: AR-blockade improved sex-bias BRAF/MEK-targeted therapy response in melanoma (115), and enhanced CD8/T-cells activity in CRPC improving PD-1/PD-L1-inhibitors response (116), suggesting that AR promote targeted and immunotherapy resistance, and shows sex impact in treatment.